Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display.

Intracellular antibodies (intrabodies) provide an attractive means for manipulating intracellular protein function, both for research and potentially for therapy. A challenge in the isolation of effective intrabodies is the ability to find molecules that exhibit sufficient binding affinity and stability when expressed in the reducing environment of the cytoplasm. Here, we have used yeast surface display of proteins to isolate novel scFv clones against huntingtin from a non-immune human antibody library. We then applied yeast surface display to affinity mature this scFv pool and analyze the location of the binding site of the mutant with the highest affinity. Interestingly, the paratope was mapped exclusively to the variable light chain domain of the scFv. A single domain antibody was constructed consisting solely of this variable light chain domain, and was found to retain full binding activity to huntingtin. Cytoplasmic expression levels in yeast of the single domain were at least fivefold higher than the scFv. The ability of the single-domain intrabody to inhibit huntingtin aggregation, which has been implicated in the pathogenesis of Huntington's disease (HD), was confirmed in a cell-free in vitro assay as well as in a mammalian cell culture model of HD. Significantly, a single-domain intrabody that is functionally expressable in the cytoplasm was derived from a non-functional scFv by performing affinity maturation and binding site analysis on the yeast cell surface, despite the differences between the cytoplasmic and extracellular environment. This approach may find application in the development of intrabodies to a wide variety of intracellular targets.

[1]  T. Rabbitts,et al.  Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation , 2003, The EMBO journal.

[2]  H. Lehrach,et al.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Andrew J. Martin,et al.  Antibody-antigen interactions: contact analysis and binding site topography. , 1996, Journal of molecular biology.

[4]  R L Stanfield,et al.  Antibody-antigen interactions: new structures and new conformational changes. , 1994, Current opinion in structural biology.

[5]  T. Rabbitts,et al.  Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. , 2002, Journal of molecular biology.

[6]  D. Curiel,et al.  Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target , 2000, Cancer Gene Therapy.

[7]  Eric T. Boder,et al.  Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.

[8]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[9]  K D Wittrup,et al.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K D Wittrup,et al.  Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. , 1999, Journal of molecular biology.

[11]  S. Jobling,et al.  Immunomodulation of enzyme function in plants by single-domain antibody fragments , 2003, Nature Biotechnology.

[12]  K. Wittrup,et al.  Rapid Method for Measuring ScFv Thermal Stability by Yeast Surface Display , 2003, Biotechnology progress.

[13]  T. Rabbitts,et al.  Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. , 2003, Journal of molecular biology.

[14]  S E Hufton,et al.  Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. , 2001, Journal of molecular biology.

[15]  M. Willingham,et al.  I ntrabody‐based strategies for inhibition of vascular endothelial growth factor receptor‐2: effects on apoptosis, cell growth, and angiogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  D. Housman,et al.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[18]  C. Raymond,et al.  General method for plasmid construction using homologous recombination. , 1999, BioTechniques.

[19]  M. Schiffer,et al.  Structure and properties of human immunoglobulin light-chain dimers. , 1995, Methods in molecular biology.

[20]  D. Danley,et al.  Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. , 1999, Journal of immunological methods.

[21]  Michele C. Kieke,et al.  Directed evolution of a stable scaffold for T-cell receptor engineering , 2000, Nature Biotechnology.

[22]  Sachdev S Sidhu,et al.  Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. , 2002, Journal of molecular biology.

[23]  P. Patterson,et al.  Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Lucy J. Holt,et al.  Domain antibodies: proteins for therapy. , 2003, Trends in biotechnology.

[25]  H R Hoogenboom,et al.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.

[26]  Kurt S. Thorn,et al.  ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions , 2001, Bioinform..

[27]  Martin R. Johnson,et al.  A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[29]  K. Wittrup,et al.  Fine Affinity Discrimination by Yeast Surface Display and Flow Cytometry , 2000, Biotechnology progress.

[30]  K Dane Wittrup,et al.  Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* , 2004, Journal of Biological Chemistry.

[31]  Andreas Plückthun,et al.  Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.

[32]  Ronald Wetzel,et al.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Cochran,et al.  Domain-level Antibody Epitope Mapping through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments , 2022 .

[34]  K. Wittrup,et al.  Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. , 2004, Nucleic acids research.

[35]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Bin Yuan,et al.  Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments† , 2004 .

[37]  H. Steven Wiley,et al.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library , 2003, Nature Biotechnology.

[38]  A. Plückthun,et al.  Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. , 1999, Journal of molecular biology.

[39]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[40]  R L Stanfield,et al.  Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Roth,et al.  Gene replacement therapy for non-small cell lung cancer: a review. , 2004, Hematology/oncology clinics of North America.

[42]  R. Murphy,et al.  A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. , 2004, Brain research. Molecular brain research.

[43]  I. Wilson,et al.  Antibody-antigen interactions , 1993 .

[44]  A. Rajpal,et al.  Intracellular Stability of Anti-caspase-3 Intrabodies Determines Efficacy in Retargeting the Antigen* , 2001, The Journal of Biological Chemistry.

[45]  David W. Colby,et al.  Engineering antibody affinity by yeast surface display. , 2004, Methods in enzymology.

[46]  K D Wittrup,et al.  Yeast surface display for directed evolution of protein expression, affinity, and stability. , 2000, Methods in enzymology.

[47]  A. Plückthun,et al.  Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria , 1999, FEBS letters.

[48]  W. Marasco,et al.  Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. , 2004, Journal of molecular biology.

[49]  T. Terwilliger,et al.  Engineering soluble proteins for structural genomics , 2002, Nature Biotechnology.